注射用拉氧头孢钠联合奥硝唑治疗盆腔炎患者的临床研究  

Clinical trial of latamoxef sodium for injection combined with ornidazole in the treatment of pelvic inflammatory disease patients

作　　者：祁雁凌 祁明花 彭新秀 宋善兰 QI Yan-ling;QI Ming-hua;PENG Xin-xiu;SONG Shan-lan(Department of Gynecology,Lianyungang Hospital of Traditional Chinese Medicine,Lianyungang 222000,Jiangsu Province,China;Department of Gynaecology,Lianyungang Maternal and Child Health Hospital,Lianyungang 222000,Jiangsu Province,China)

机构地区：[1]连云港市中医院妇科,江苏连云港222000 [2]连云港市妇幼保健院妇科,江苏连云港222000

出　　处：《中国临床药理学杂志》2023年第4期474-477,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨注射用拉氧头孢钠联合奥硝唑治疗盆腔炎患者的临床疗效及安全性。方法将盆腔炎患者随机分为对照组和试验组。对照组将拉氧头孢钠1.0 g溶于生理盐水250 mL中,静脉滴注,每天2次;试验组在对照组治疗的基础上静脉滴注奥硝唑注射液,每次0.5 g,每天2次。2组均连续治疗10 d。比较2组患者的临床疗效,治疗前后的炎性因子[白细胞计数(WBC)、C反应蛋白(CRP)和降钙素原(PCT)]水平,评价治疗前后月经不调、腰骶疼痛、发热乏力、白带增多的临床症状评分以及药物不良反应发生情况。结果试验组和对照组均分别纳入45例患者。治疗后,对照组和试验组临床总有效率分别为77.78%和93.33%,差异有统计学意义(P<0.05)。对照组和试验组血清WBC水平分别为(9.36±1.17)×10^(9)/L,(7.56±0.49)×10^(9)/L;血清CRP水平分别为(11.18±1.30),(7.81±1.23)mg·L^(-1);血清PCT水平分别为(0.98±0.35),(0.37±0.29)μg·L^(-1),差异均有统计学意义(均P<0.05)。对照组和试验组月经不调评分分别为(12.42±0.97),(9.76±0.93)分;腰骶疼痛评分分别为(11.11±1.35),(8.00±1.22)分;发热乏力评分分别为(13.31±1.43),(9.40±1.21)分;白带增多评分分别为(9.80±1.78),(7.91±1.65)分;下腹部疼痛评分分别为(10.43±1.10),(8.01±1.21)分,差异均有统计学意义(均P<0.05)。对照组和试验组的药物不良反应发生率分别为8.88%和11.11%,差异无统计学意义(P>0.05)。结论拉氧头孢钠联合奥硝唑治疗盆腔炎的临床效果显著,可显著改善患者的临床症状,降低机体的炎症反应,安全性高。Objective To investigate the clinical efficacy and safety of latamoxef sodium for injection combined with ornidazole in the treatment of pelvic inflammatory disease.Methods The patients with pelvic inflammatory disease were randomly divided into control group and treatment group.Control group was given latamoxef sodium 1.0 g dissolved in normal saline 250 m L for intravenous infusion,twice a day.On the basis of control group,treatment group was given ornidazole injection,0.5 g a time,intravenous drip,twice a day.Both groups were treated continuously for 10 days.The clinical efficacy and the levels of inflammatory factors[white blood cell (WBC),C-reactive protein(CRP) and procalcitonin (PCT)]before and after treatment were compared between the two groups.Clinical symptom scores of irregular menstruation,lumbosacral pain,fever and fatigue,increased leucorrhea,and the occurrence of adverse drug reactions were compared.Results The control group and the treatment group were both 45 cases.After treatment,the total clinical effective rates of control group and treatment group were 77.78%and 93.33%,respectively,the difference was statistically significant (P<0.05).The serum WBC levels in control group and treatment group were(9.36±1.17)×10^(9)/L and (7.56±0.49)×10^(9)/L;the serum CRP levels were (11.18±1.30) and(7.81±1.23) mg·L^(-1);the serum PCT levels were respectively were (0.98±0.35) and (0.37±0.29)μg·L-1,the differences were statistically significant (all P<0.05).The scores of irregular menstruation in control group and treatment group were (12.42±0.97) and (9.76±0.93) points;the lumbosacral pain scores were 11.11±1.35 and8.00±1.22;and the fever and fatigue scores were 13.31±1.43 and 9.40±1.21;and the increased leucorrhea scores were 9.80±1.78 and 7.91±1.65;the scores of lower abdominal pain were 10.43±1.10 and 8.01±1.21,respectively,the differences were statistically significant (all P<0.05).The incidences in control group and treatment group were 8.88%and 11.11%,without significant difference

关 键 词：拉氧头孢钠 奥硝唑 盆腔炎 炎性因子 

分 类 号：R972[医药卫生—药品]